Literature DB >> 30231184

The Conservative Treatment of Osteoarthritis of the Knee.

Jack M Bert, Nathan K Endres, Christopher J Tucker, Annabelle P Davey.   

Abstract

Osteoarthritis has one of the highest associations for all-cause mortality in the United States. Comorbidities are common in patients with end-stage disease. In most cases, it is critical to exhaust conservative modalities of care before resorting to surgical intervention. This article discusses common conservative approaches focusing on injectable treatments that can be employed prior to total knee replacement. [Orthopedics. 2018; 41(5):256-260.]. Copyright 2018, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30231184     DOI: 10.3928/01477447-20180828-08

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  4 in total

1.  The Efficacy of Ozone Prolotherapy Compared to Intra-Articular Hypertonic Saline Injection in Reducing Pain and Improving the Function of Patients with Knee Osteoarthritis: A Randomized Clinical Trial.

Authors:  Hamid Reza Farpour; Alireza Ashraf; Seyed Saeed Hosseini
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-03       Impact factor: 2.629

2.  Medium-term efficacy of arthroscopic debridement vs conservative treatment for knee osteoarthritis of Kellgren-Lawrence grades I-III.

Authors:  Bo Lv; Kai Huang; Jun Chen; Zhuo-Yi Wu; Hua Wang
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

3.  Plasma miR-200c-3p, miR-100-5p, and miR-1826 serve as potential diagnostic biomarkers for knee osteoarthritis: Randomized controlled trials.

Authors:  Zhen Lai; Yanguang Cao
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

4.  Trends of Total Knee Arthroplasty According to Age Structural Changes in Korea from 2011 to 2018.

Authors:  Yong-Beom Kim; Hyung-Suk Choi; Eun Myeong Kang; Suyeon Park; Gi-Won Seo; Dong-Il Chun; Tae-Hong Min
Journal:  Int J Environ Res Public Health       Date:  2021-12-20       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.